Safety of and Immune Response to an Experimental HIV Vaccine (VRC-HIVADV014-00-VP) in HIV Uninfected Adults

October 13, 2021 updated by: National Institute of Allergy and Infectious Diseases (NIAID)

A Phase I Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade, Multivalent Recombinant Adenoviral Vector HIV Vaccine, VRC-HIVADV014-00-VP, in Healthy, HIV-1 Uninfected Adult Participants Who Have Low Titers of Pre-Existing Ad5 Neutralizing Antibodies

The purpose of this study is to determine the safety of and immune response to an experimental HIV vaccine in HIV uninfected individuals.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

The HIV epidemic is a major global health challenge. People in developing nations have limited access to life-sustaining antiretrovirals and account for over 95% of the 5 million new HIV infections annually. The development of a safe, effective, and widely accessible HIV vaccine is paramount in these areas. The adenoviral vector vaccine VRC-HIVADV014-00-VP has been shown to elicit a CD8 cytotoxic lymphocyte (CTL) response believed to be crucial in an effective preventive HIV vaccine. The purpose of this study is to determine the safety and immunogenicity of VRC-HIVADV014-00-VP in HIV uninfected adults. In this study, HIV uninfected individuals with low levels of pre-existing adenovirus neutralizing antibodies will receive different doses of the preventive vaccine to determine its safety, tolerability, and immunogenicity.

This study will last 1 year. Participants will be randomly assigned to one of two groups. At study entry, participants in each group will receive a single injection of either one of two doses of the adenoviral vector vaccine or placebo. Participants will record their temperature and other side effects in a symptom log on the day of vaccination and for 3 days thereafter. Participants will have seven clinic visits over 12 months. A physical exam, HIV and pregnancy prevention counseling, and blood and urine collection will occur at each visit. Participants will also be asked about side effects they may be experiencing and medications they are taking.

Study Type

Interventional

Enrollment (Actual)

48

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • San Francisco, California, United States
        • San Francisco Vaccine and Prevention CRS
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt Vaccine CRS
    • Washington
      • Seattle, Washington, United States, 98104
        • FHCRC/UW Vaccine CRS

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 50 years (ADULT)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Have access to a participating site and are willing to be followed for the duration of the study
  • Willing to receive HIV test results
  • Able to understand and comply with study requirements
  • In good general health
  • Have neutralizing adenovirus antibody levels that are less than a 1:12 ratio
  • Agree to use acceptable methods of contraception for at least 21 days prior to study start and for the duration of the study.

Exclusion Criteria:

  • HIV infected
  • Positive hepatitis B surface antigen
  • Positive anti-hepatitis C virus antibodies
  • Prior receipt of an HIV vaccine
  • Immunosuppressive drugs within 168 days prior to first vaccination
  • Have received donated blood within 120 days prior to first vaccination
  • Have received immunoglobulin within 60 days of the first vaccination
  • Live attenuated vaccines or investigational research agents within 30 days prior to first vaccination
  • Subunit or killed vaccines within 14 days prior to first vaccination
  • Current preventive or therapeutic anti-tuberculosis (TB) treatment
  • Any medical, psychiatric, or social condition that would interfere with the study
  • Any occupational or other responsibility that would interfere with the study
  • Serious adverse reactions to vaccines
  • Autoimmune disease
  • Immunodeficiency
  • Active syphilis infection. Participants who have been fully treated for syphilis over 6 months prior to study entry are not excluded.
  • Asthma. Participants who have had completely resolved childhood asthma are not excluded.
  • Diabetes mellitus type I or II. Participants who have had isolated gestational diabetes are not excluded.
  • Thyroid disease or removal of the thyroid
  • Blood vessel swelling within the last 3 years
  • Uncontrolled hypertension
  • Body mass index (BMI) of 40 or higher
  • Bleeding disorder
  • Cancer. Participants whose cancer has been removed and is unlikely to recur during the study are not excluded.
  • Seizure disorder. Participants who have not required medication or had a seizure for 3 years prior to study entry are not excluded.
  • Removal of the spleen or have a nonfunctioning spleen
  • Psychiatric conditions that may interfere with the study
  • Pregnancy, breastfeeding, or plan to become pregnant during the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: DOUBLE

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Blood and chemical parameters for 12 months after injection
Local and systemic adverse reactions for 12 months after injection

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators

  • Study Chair: Laurence Peiperl, MD, San Francisco Department of Public Health

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Completion (ACTUAL)

October 1, 2006

Study Registration Dates

First Submitted

July 12, 2005

First Submitted That Met QC Criteria

July 12, 2005

First Posted (ESTIMATE)

July 14, 2005

Study Record Updates

Last Update Posted (ACTUAL)

October 14, 2021

Last Update Submitted That Met QC Criteria

October 13, 2021

Last Verified

October 1, 2021

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • HVTN 054
  • 10121 (DAIDS ES Registry Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on HIV Infections

Clinical Trials on VRC-HIVADV014-00-VP

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Thailand

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe